31/07/2026 FDA grants tentative approval for OMCAZIO, a lower-dose Cabozantinib formulation with improved absorption Annamycin shows 37% CRc in Venetoclax-failed AML patients, with unblinded arms reaching up to 57% FDA grants tentative approval for OMCAZIO, a lower-dose Cabozantinib formulation with improved absorption (Ref) Handa Oncology announced that the US FDA has granted tentative approval for OMCAZIO (cabozantinib; multikinase inhibitor) capsules, a novel alternate-sal